In fact, ICI targeting Tim-3 or Lag-3 are progressing in Phase I clinical trial, such as the monotherapy with anti-Lag-3 mAb in patients with advanced solid tumor malignancies or lymphomas (ClinicalTrials.gov Identifier: NCT03489369), and the combination therapy using anti-Lag-3 mAb and anti-PD-1 mAb in patients with recurrent glioblastoma (ClinicalTrials.gov Identifier: NCT02658981) and using anti-Tim-3 mAb and anti-PD-1 mAb in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT02817633). The gene discussed is HAVCR2; the disease is lymphoma.